TY - JOUR
T1 - Essential thrombocythemia: Baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients
AU - Angona, Anna
AU - Alvarez-Larrán, Alberto
AU - Bellosillo, Beatriz
AU - Martínez-Avilés, Luz
AU - Garcia-Pallarols, Francesc
AU - Longarón, Raquel
AU - Ancochea, Àgueda
AU - Besses, Carles
PY - 2015/3/15
Y1 - 2015/3/15
N2 - © 2014 Elsevier España, S.L.U. All rights reserved. Background and objective Two prognostic models to predict overall survival and thrombosis-free survival have been proposed: International Prognostic Score for Essential Thrombocythemia (IPSET) and IPSET-Thrombosis, respectively, based on age, leukocytes count, history of previous thrombosis, the presence of cardiovascular risk factors and the JAK2 mutational status. The aim of the present study was to assess the clinical and biological characteristics at diagnosis and during evolution in essential thrombocythemia (ET) patients as well as the factors associated with survival and thrombosis and the usefulness of these new prognostic models. Patients and methods We have evaluated the clinical data and the mutation status of JAK2, MPL and calreticulin of 214 ET patients diagnosed in a single center between 1985 and 2012, classified according to classical risk stratification, IPSET and IPSET-Thrombosis. Results With a median follow-up of 6.9 years, overall survival was not associated with any variable by multivariate analysis. Thrombotic history and leukocytes > 10 × 109/l were associated with thrombosis-free survival (TFS). In our series, IPSET prognostic systems of survival and thrombosis did not provide more clinically relevant information regarding the classic risk of thrombosis stratification. Conclusion Thrombotic history and leukocytosis > 10× 109/l were significantly associated with lower TFS, while the prognostic IPSET-Thrombosis system did not provide more information than classical thrombotic risk assessment.
AB - © 2014 Elsevier España, S.L.U. All rights reserved. Background and objective Two prognostic models to predict overall survival and thrombosis-free survival have been proposed: International Prognostic Score for Essential Thrombocythemia (IPSET) and IPSET-Thrombosis, respectively, based on age, leukocytes count, history of previous thrombosis, the presence of cardiovascular risk factors and the JAK2 mutational status. The aim of the present study was to assess the clinical and biological characteristics at diagnosis and during evolution in essential thrombocythemia (ET) patients as well as the factors associated with survival and thrombosis and the usefulness of these new prognostic models. Patients and methods We have evaluated the clinical data and the mutation status of JAK2, MPL and calreticulin of 214 ET patients diagnosed in a single center between 1985 and 2012, classified according to classical risk stratification, IPSET and IPSET-Thrombosis. Results With a median follow-up of 6.9 years, overall survival was not associated with any variable by multivariate analysis. Thrombotic history and leukocytes > 10 × 109/l were associated with thrombosis-free survival (TFS). In our series, IPSET prognostic systems of survival and thrombosis did not provide more clinically relevant information regarding the classic risk of thrombosis stratification. Conclusion Thrombotic history and leukocytosis > 10× 109/l were significantly associated with lower TFS, while the prognostic IPSET-Thrombosis system did not provide more information than classical thrombotic risk assessment.
KW - Calreticulin
KW - Essential thrombocythemia
KW - JAK2V617F
KW - Survival
KW - Thrombosis
U2 - 10.1016/j.medcli.2014.04.029
DO - 10.1016/j.medcli.2014.04.029
M3 - Article
VL - 144
SP - 247
EP - 253
IS - 6
ER -